Breaking News Instant updates and real-time market news.

ESPR

Esperion

$41.22

17.55 (74.14%)

05:56
03/21/17
03/21
05:56
03/21/17
05:56

Esperion price target raised to $50 from $22 at JPMorgan

JPMorgan analyst Jessica Fye raised her price target for Esperion Therapeutics to $50 citing the company's "positive" regulatory update on bempedoic acid. The analyst pulled forward her U.S. launch assumption to 2020 from 2023 and increased her probability of success in the U.S. to 75%. Fye keeps a Neutral rating on the shares, however, citing fewer catalysts to drive upside in 2017.

  • 28

    Mar

ESPR Esperion
$41.22

17.55 (74.14%)

03/20/17
FBCO
03/20/17
UPGRADE
FBCO
Neutral
Esperion upgraded to Neutral from Underperform at Credit Suisse
03/20/17
SBSH
03/20/17
NO CHANGE
Target $39
SBSH
Buy
Esperion likely needs to raise cash before FDA approval, says Citi
Following the company's conference call last night, Citi analyst Joel Beatty continues to believe Esperion Therapeutics' bempedoic acid could be approved by FDA based on LDL lowering as a surrogate endpoint. The company will likely need to raise capital before a potential FDA approval, however, Beatty tells investors in a research note. Further, the FDA is unlikely to provide clarity on LDL as a surrogate ahead of a filing in early 2019, the analyst adds. He keeps a Buy rating on Esperion with a $39 price target. The stock in early trading is up 55%, or $13.03, to $36.70.
03/20/17
JPMS
03/20/17
NO CHANGE
JPMS
Neutral
Esperion LDL-C lowering endpoint news a clear positive, says JPMorgan
After Esperion (ESPR) announced that the FDA confirmed that the bempedoic acid phase 3 program is adequate to support approval of an LDL-C lowering indication prior to outcomes data, JPMorgan analyst Jessica Fye said some expectation for this type of update "started to come into the stock" after Amgen's (AMGN) release of the FOURIER trial top-line results on last Friday. Still, the news is a clear positive for Esperion as it lifts one of the largest overhangs on the stock over the past 18 months. Fye, who now sees the potential for approval of bempedoic acid in 2020, keeps a Neutral rating on Esperion shares.
03/20/17
JMPS
03/20/17
NO CHANGE
Target $60
JMPS
Outperform
Esperion price target raised to $60 from $41 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Esperion Therapeutics to $60 from $41 after the FDA confirmed that the company can pursue approval for bempedoic acid for an LDL-C lowering indication, which he believes supports NDA submission in 1H19 and a potential launch in 2020 and addresses a key investor concern. The analyst, who moved up his launch assumption and increased the probability of success for the drug to 75% from 67%, keeps an Outperform rating on Esperion shares.

TODAY'S FREE FLY STORIES

18:25
03/27/17
03/27
18:25
03/27/17
18:25
Conference/Events
Federal Reserve Bank of Dallas President speaks on monetary policy »

Dallas Federal Reserve…

EEI

Ecology & Environment

$9.90

-0.1 (-1.00%)

18:19
03/27/17
03/27
18:19
03/27/17
18:19
Hot Stocks
Ecology & Environment board urges shareholders to vote for company's nominees »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDLI

PDL BioPharma

$2.05

0.07 (3.54%)

18:16
03/27/17
03/27
18:16
03/27/17
18:16
Hot Stocks
PDL BioPharma CFO discloses purchase of 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:15
03/27/17
03/27
18:15
03/27/17
18:15
General news
Breaking General news story  »

Dallas Federal Reserve…

RAVN

Raven

$29.75

0.45 (1.54%)

18:14
03/27/17
03/27
18:14
03/27/17
18:14
Hot Stocks
Raven CEO says 'entering fiscal year 2018 from a position of strength' »

"We are very pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

RAVN

Raven

$29.75

0.45 (1.54%)

18:12
03/27/17
03/27
18:12
03/27/17
18:12
Hot Stocks
Breaking Hot Stocks news story on Raven »

Raven sees FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

RAVN

Raven

$29.75

0.45 (1.54%)

18:11
03/27/17
03/27
18:11
03/27/17
18:11
Earnings
Raven reports Q4 EPS 12c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

OREX

Orexigen

$4.13

0.15 (3.77%)

18:05
03/27/17
03/27
18:05
03/27/17
18:05
Hot Stocks
Orexigen, Bruno reach distribution agreement for Mysimba »

Orexigen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

HUN

Huntsman

$22.89

0.24 (1.06%)

18:01
03/27/17
03/27
18:01
03/27/17
18:01
Hot Stocks
Huntsman moves up after projecting Q1 adjusted EBITDA to rise YoY »

Shares of chemical maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PFE

Pfizer

$34.18

0.18 (0.53%)

, BMY

Bristol-Myers

$56.04

0.15 (0.27%)

18:00
03/27/17
03/27
18:00
03/27/17
18:00
Hot Stocks
Credit Suisse analysis shows value in hypothetical Pfizer-Bristol merger »

Credit Suisse analysts…

PFE

Pfizer

$34.18

0.18 (0.53%)

BMY

Bristol-Myers

$56.04

0.15 (0.27%)

NVS

Novartis

$75.10

0.73 (0.98%)

GILD

Gilead

$67.50

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 06

    Jun

  • 26

    Jun

  • 27

    Aug

VRX

Valeant

$10.81

0.06 (0.56%)

18:00
03/27/17
03/27
18:00
03/27/17
18:00
Periodicals
Ex-Valeant CEO Pearson sues company over unpaid compensation, WSJ says »

Former Valeant CEO Mike…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

DGLY

Digital Ally

$4.60

0.49 (11.92%)

, TASR

Taser

$22.47

-0.03 (-0.13%)

17:54
03/27/17
03/27
17:54
03/27/17
17:54
Earnings
Digital Ally reports Q4 adjusted EPS (63c), two estimates (20c) »

Reports Q4 revenue…

DGLY

Digital Ally

$4.60

0.49 (11.92%)

TASR

Taser

$22.47

-0.03 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

AEM

Agnico Eagle

$44.64

0.81 (1.85%)

17:51
03/27/17
03/27
17:51
03/27/17
17:51
Syndicate
Agnico Eagle to sell approximately 5M shares to institutional investor »

Agnico Eagle Mines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

  • 28

    Apr

HUN

Huntsman

$22.89

0.24 (1.06%)

17:50
03/27/17
03/27
17:50
03/27/17
17:50
Hot Stocks
Huntsman sees Q1 adjusted EBITDA to exceed the $274M reported in 1Q16 »

Huntsman Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

SELB

Selecta Biosciences

$11.92

-0.12 (-1.00%)

, RHT

Red Hat

$82.20

-0.76 (-0.92%)

17:43
03/27/17
03/27
17:43
03/27/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SELB

Selecta Biosciences

$11.92

-0.12 (-1.00%)

RHT

Red Hat

$82.20

-0.76 (-0.92%)

SNX

SYNNEX

$118.32

1.38 (1.18%)

PSIX

Power Solutions

$6.40

0.07 (1.11%)

OCN

Ocwen

$4.89

0.08 (1.66%)

TSRO

Tesaro

$156.73

-3.27 (-2.04%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FMSA

Fairmount Santrol

$6.74

-0.08 (-1.17%)

HCLP

Hi-Crush Partners

$15.40

0.05 (0.33%)

DECK

Deckers Brands

$56.51

0.23 (0.41%)

CYRX

Cryoport

$3.75

0.2219 (6.29%)

EVH

Evolent Health

$21.25

0.4 (1.92%)

STOR

STORE Capital

$23.46

-0.25 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 04

    Apr

  • 06

    Apr

  • 12

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 30

    Jun

ADHD

Alcobra

17:41
03/27/17
03/27
17:41
03/27/17
17:41
Hot Stocks
Brosh raises stake in Alcobra to 10.9% ahead of investor meeting »

Brosh Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PSIX

Power Solutions

$6.40

0.07 (1.11%)

17:33
03/27/17
03/27
17:33
03/27/17
17:33
Hot Stocks
Weichai America to invest $60M in Power Solutions »

Power Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RADA

RADA Electronic

$1.15

-0.04 (-3.36%)

17:32
03/27/17
03/27
17:32
03/27/17
17:32
Syndicate
Breaking Syndicate news story on RADA Electronic »

RADA Electronic files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$17.15

0.34 (2.02%)

17:29
03/27/17
03/27
17:29
03/27/17
17:29
Syndicate
Breaking Syndicate news story on iShares Silver Trust »

iShares Silver Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAU

iShares Gold Trust

$12.08

0.07 (0.58%)

17:28
03/27/17
03/27
17:28
03/27/17
17:28
Syndicate
Breaking Syndicate news story on iShares Gold Trust »

iShares Gold Trust files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GABC

German American Bancorp

$44.33

-0.33 (-0.74%)

17:25
03/27/17
03/27
17:25
03/27/17
17:25
Hot Stocks
German American Bancorp announces 3-for-2 stock split »

German American Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$0.95

0.2215 (30.34%)

17:18
03/27/17
03/27
17:18
03/27/17
17:18
Hot Stocks
Staffing 360 Solutions, board reject buy-out offer from Jackson Investment Group »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$15.40

-0.24 (-1.53%)

17:16
03/27/17
03/27
17:16
03/27/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Canada Goose »

Adage Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$140.32

-0.02 (-0.01%)

, AAPL

Apple

$140.88

0.24 (0.17%)

17:14
03/27/17
03/27
17:14
03/27/17
17:14
Periodicals
Facebook hires Apple vet to lead Oculus hardware efforts, Bloomberg says »

Facebook (FB) has hired…

FB

Facebook

$140.32

-0.02 (-0.01%)

AAPL

Apple

$140.88

0.24 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

ISTR

Investar Holding

$22.15

0.1 (0.45%)

17:13
03/27/17
03/27
17:13
03/27/17
17:13
Hot Stocks
Breaking Hot Stocks news story on Investar Holding »

EJF Capital reports 6.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.